Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Accumulated Expenses: 2023-2024

Historic Other Accumulated Expenses for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $3.4 million.

  • Monte Rosa Therapeutics' Other Accumulated Expenses rose 104.68% to $4.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $4.4 million, marking a year-over-year increase of 104.68%. This contributed to the annual value of $3.4 million for FY2024, which is 100.72% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Other Accumulated Expenses of $3.4 million as of FY2024, which was up 100.72% from $1.7 million recorded in FY2023.
  • Over the past 5 years, Monte Rosa Therapeutics' Other Accumulated Expenses peaked at $3.4 million during FY2024, and registered a low of $1.7 million during FY2023.
  • Moreover, its 2-year median value for Other Accumulated Expenses was $2.5 million (2023), whereas its average is $2.5 million.
  • Data for Monte Rosa Therapeutics' Other Accumulated Expenses shows a peak YoY spiked of 100.72% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Monte Rosa Therapeutics' Other Accumulated Expenses stood at $1.7 million in 2023, then soared by 100.72% to $3.4 million in 2024.